Penumbra (PEN) Net Income towards Common Stockholders (2014 - 2026)
Penumbra's (PEN) quarterly Net Income towards Common Stockholders came in at $32.6 million in Q1 2026, down 16.92% year-on-year from $39.2 million in Q1 2025, and down 31.17% on a QoQ basis from $47.3 million in Q4 2025.
Penumbra (PEN) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Net Income towards Common Stockholders data on file, last reported at $32.6 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 16.92% year-over-year to $32.6 million in Q1 2026; TTM through Mar 2026 was $171.1 million, a 305.59% increase from a year earlier, with the FY2025 full-year figure at $177.7 million, up 1168.11% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at $32.6 million, down from $47.3 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for PEN reached as high as $54.2 million in Q4 2023 and fell as low as -$60.2 million in Q2 2024.
- Historically, Net Income towards Common Stockholders has averaged $18.4 million across 5 years, with a median of $18.9 million in 2023.
- Across the five-year window, Net Income towards Common Stockholders jumped 10737.97% in 2023 and slumped 417.91% in 2024, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at $3.9 million in 2022, then surged by 1298.45% to $54.2 million in 2023, then plunged by 37.88% to $33.7 million in 2024, then soared by 40.56% to $47.3 million in 2025, then slumped by 31.17% to $32.6 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $32.6 million in Q1 2026, $47.3 million in Q4 2025, and $45.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.88 Bn | 176.59 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.94 Bn | 126.06 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.75 Bn | 99.53 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.65 Bn | 67.19 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.22 Bn | 44.55 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.43 Bn | 27.31 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 28.32 Bn | 26.03 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.10 Bn | 21.98 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Penumbra | 12.58 Bn | 11.97 Bn | 253.41 Mn | 32.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.59 Mn |
| Dec 31, 2025 | 47.34 Mn |
| Sep 30, 2025 | 45.85 Mn |
| Jun 30, 2025 | 45.31 Mn |
| Mar 31, 2025 | 39.22 Mn |
| Dec 31, 2024 | 33.68 Mn |
| Sep 30, 2024 | 29.48 Mn |
| Jun 30, 2024 | -60.20 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Dec 31, 2023 | 54.22 Mn |
| Sep 30, 2023 | 9.21 Mn |
| Jun 30, 2023 | 18.94 Mn |
| Mar 31, 2023 | 8.56 Mn |
| Dec 31, 2022 | 3.88 Mn |
| Sep 30, 2022 | -2.27 Mn |
| Jun 30, 2022 | -3.69 Mn |
| Mar 31, 2022 | 79,000.00 |
| Dec 31, 2021 | -24.63 Mn |
| Sep 30, 2021 | 8.03 Mn |
| Jun 30, 2021 | 8.30 Mn |